OncoMatch/Clinical Trials/NCT05833438
Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy
Is NCT05833438 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies VEN+AZA-5 for acute myeloid leukemia (aml).
Treatment: VEN+AZA-5 — Acute myeloid leukemia (AML): continuous oral Venetoclax (VEN) and 7 days of s.c. Azacitidine (AZA) per 28-day cycle = standard of care for intensive induction therapy ineligible AML patients in Germany The VENAZA-5S pilot trial: AZA administration reduced to 5 days within each cycle to improve tolerability and treatment adherence due to less neutropenic infections, less treatment interruptions and less hospitalizations.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Prior therapy
Cannot have received: hypomethylating agent
Exception: Prior use of hydroxyurea is allowed
Prior treatment for AML or myelodysplastic syndrome (MDS) with one of the following: Hypomethylating agent (HMA)
Cannot have received: chemotherapeutic agent
Exception: Prior use of hydroxyurea is allowed
Prior treatment for AML or myelodysplastic syndrome (MDS) with one of the following: Chemotherapeutic agent
Cannot have received: CAR-T cell therapy
Exception: Prior use of hydroxyurea is allowed
Prior treatment for AML or myelodysplastic syndrome (MDS) with one of the following: Chimeric Antigen Receptor (CAR)-T cell therapy
Cannot have received: experimental therapies
Exception: Prior use of hydroxyurea is allowed
Prior treatment for AML or myelodysplastic syndrome (MDS) with one of the following: Experimental therapies
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify